Objective-In vitro studies showed that insulin stimulates the production of apolipoprotein AI (apoAI). Thus, we hypothesized that chronic hyperinsulinemia could contribute to the increase in the production of high-density lipoprotein apoAI that is observed in metabolic syndrome. Approach and Results-We performed an in vivo kinetic study with stable isotope in 7 patients with insulinoma who showed hyperinsulinemia but no insulin resistance, 8 patients with insulin resistance, and 16 controls. Insulinemia was 3.1× (P<0.01) higher in patients with insulinoma or insulin resistance than in controls in the fasting state and, respectively, 3.5× and 2.6× (P<0.05) higher in the fed state. The high-density lipoprotein apoAI pool size was smaller in patients with insulin resistance than in controls (49.3±5.4 versus 59.6±7.7 mg·kg −1 ; P<0.01), whereas both the highdensity lipoprotein apoAI fractional catabolic rate and the high-density lipoprotein apoAI production rate were higher (0.30±0.07 versus 0.20±0.04 pool·d −1 ; P<0.0001 and 14.6±1.5 versus 11.5±1.9 mg·kg −1 ·d −1 ; P<0.01, respectively). In contrast, no significant difference was observed for these parameters between patients with insulinoma and controls.
L ow high-density lipoprotein (HDL) cholesterol and apolipoprotein AI (apoAI) concentrations are a key feature of metabolic syndrome and are likely to play a central role in the early development of atherosclerotic lesions in patients presenting with this syndrome. [1] [2] [3] Numerous kinetic studies have shown that the decrease in apoAI stems from a faster catabolic rate, which is observed early in patients with metabolic syndrome when glycemia is still normal, and worsens in patients with type 2 diabetes mellitus, in whom it can reach +90%. [4] [5] [6] [7] [8] [9] [10] [11] The increase in the HDL apoAI fractional catabolic rate (FCR) is mainly explained by the remodeling of HDL particles under the combined action of cholesteryl ester transfer protein and hepatic lipase, the activities of which are increased in metabolic syndrome. Moreover, a lower concentration of adiponectin could also contribute to faster apoAI catabolism because a significant negative correlation between HDL apoAI catabolism and plasma adiponectin, independently of abdominal obesity, insulin sensitivity, age, sex, and plasma lipids, has been reported. 12 In addition to the increased HDL apoAI FCR, several studies also showed an increase in the HDL apoAI production rate (PR). [4] [5] [6] [7] [8] This increase is usually smaller than the increase in the FCR, but it explains why the concentration of HDL apoAI is decreased to a lesser extent than we could expect in view of the FCR values. The mechanisms underlying the increase in the apoAI PR are not clear. In vitro studies have demonstrated that insulin stimulates the transcription of apoAI via the transcription factor Sp. [13] [14] [15] It has been postulated that hyperinsulinemia observed in patients with metabolic syndrome could contribute to the increase in the apoAI PR associated with this syndrome. 16 However, because these patients with metabolic syndrome are also insulin resistant, the exact role of hyperinsulinemia in the increased apoAI PR observed in metabolic syndrome is not clear.
To clarify whether hyperinsulinemia may play a role in the apoAI PR, we set up a kinetic study in patients with insulinoma showing chronic hyperinsulinemia but no insulin resistance to test whether hyperinsulinemia could directly increase the HDL apoAI PR. We compared the results observed with those for patients with metabolic syndrome associated with both hyperinsulinemia and insulin resistance and those for controls with neither hyperinsulinemia nor insulin resistance.
Materials and Methods

Materials and methods are provided in the online-only Supplement
Results
Measurement of Glycemia and Insulin Sensitivity
Mean body mass index in patients with insulinoma and controls was similar, whereas it was 1.6× and 1.5× higher in insulin-resistant subjects than in controls and patients with insulinoma, respectively (P<0.0001; Table 1 ). The serum glucose level was significantly lower in patients with insulinoma than in controls and insulin-resistant subjects both in the fasting state (−1.39 and −2.00 mmol·L −1 , respectively; P<0.0001) and during the kinetic study in the fed state (−1.59; P=0.012 and −2.75 mmol·L −1 ; P<0.0001, respectively). Serum glucose level was moderately higher in insulin-resistant subjects than in controls both in the fasting (+0.61 mmol·L −1 ; P=0.028) and in the fed state (+1.16 mmol·L −1 ; P=0.024). Control subjects showed normal insulin sensitivity (homeostasis model assessment, 1.02±0.28). Patients with insulinoma had higher fasting serum insulin levels than controls (14.8±8.3 versus 4.8±1.6 mU·L −1 ; P=0.003) and normal steady-state plasma glucose values, indicating the absence of insulin resistance. In the fed state, the mean serum insulin level was also significantly higher in patients with insulinoma than in control subjects (30.1±15.5 versus 8.5±5.7 mU·L −1 ; P=0.024). Patients with insulin resistance were hyperinsulinemic compared with control subjects both in the fasting (14.7±8.0 versus 4.8±1.6 mU·L −1 ; P=0.002) and in the fed state (22.1±3.7 versus 8.5±5.7 mU·L −1 ; P=0.033). The steady-state plasma glucose at 13.28±4.87 mmol·L −1 proved that they were markedly insulin resistant. This value was far higher than that observed in patients with insulinoma (13.28±4.87 versus 4.42±2.58 mmol·L −1 ; P=0.001). The serum insulin level in patients with insulinoma was similar to that in patients with insulin resistance both in the fasting and in the fed state.
Serum Lipid Parameters
There was no difference between patients with insulinoma and controls for the fasting serum triglyceride level and HDL cholesterol concentration (Table 1 ). In contrast, the fasting triglyceride level in insulin-resistant subjects was twice that in controls (1.50±0.66 versus 0.75±0.33 mmol·L −1 ; P=0.0004) and HDL cholesterol concentration was 26% lower (1.11±0.28 versus 1.51±0.26 mmol·L −1 ; P=0.003) than that in controls. Similarly, the serum triglyceride level was 1.9× higher (1.50±0.60 versus 0.80±0.28 mmol·L −1 ; P=0.004) and the HDL cholesterol concentration was 22% lower (1.11±0.28 versus 1.43±0.34 mmol·L −1 ; P=0.036) in patients with insulin resistance than in patients with insulinoma. There was no difference among the 3 groups of subjects for fasting serum concentrations of total and low-density lipoprotein cholesterol.
HDL Composition
HDLs from patients with insulin resistance were 1.9× and 1.8× richer in triglycerides than were HDLs from controls (P=0.002) and patients with insulinoma (P=0.027), respectively ( Table 2) . In contrast, HDLs from patients with insulin resistance was 17% less rich in cholesteryl esters than were HDLs from controls (P=0.009) and patients with insulinoma (P=0.033). The percentage of proteins, free cholesterol, and phospholipids was similar in the 3 groups.
ApoAI Kinetic Parameters
Kinetic curves are shown in Figure 1 for the 3 groups of subjects.
The serum HDL apoAI pool size in patients with insulinoma was similar to that in controls (56.3±8.6 versus 59.6±7.7 mg·kg −1 ; P=0.34; Figure 2 ). In contrast, it was significantly lower in patients with insulin resistance than in controls (49.3±5.4 versus 59.6±7.7 mg·kg −1 ; P=0.003) and tended to be lower than in patients with insulinoma (49.3±5.4 versus 56.3±8.6 mg·kg −1 ; P=0.078). The HDL apoAI FCR in patients with insulinoma was similar to that in controls (0.20±0.06 versus 0.20±0.04 pool·d −1 ; P=0.88). It was 1.5× higher in patients with insulin resistance than in controls (0.30±0.07 versus 0.20±0.04 pool·d −1 ; P<0.0001) and in patients with insulinoma (0.30±0.07 versus 0.20±0.06 pool·d −1 ; P=0.0011). The HDL apoAI PR in patients with insulinoma was very similar to that in controls (11.1±1.6 versus 11.5±1.9 mg·kg −1 ·d −1 ; P=0.72), whereas it was 27% and 232% higher in patients with insulin resistance than in controls (14.6±1.5 versus 11.5±1.9 mg·kg −1 ·d −1 ; P=0.003) and in patients with insulinoma (14.6±1.5 versus 11.1±1.6 mg·kg −1 ·d −1 ; P=0.005), respectively.
Correlations
In univariate analysis, the HDL apoAI PR correlated with the HDL apoAI FCR in the control group (r=0.69; P=0.007), in patients with insulinoma (r=0.79; P=0.050), and in patients with insulin resistance (r=0.81; P=0.032; Table 3 ). In multiregression analysis, with the apoAI PR as a dependent variable and the apoAI FCR, HDL triglyceride content, the presence of insulin resistance (yes/no), the pathology (insulinoma, insulin resistance, none), age, and sex as independent variables, only the apoAI FCR was significantly correlated with the apoAI PR and explained 80% of the variance of the apoAI PR (β=6.56; P<0.0001; Figure 3 ).
Discussion
This stable isotope kinetic study of HDL apoAI conducted in patients with insulinoma, a very rare pathology, showed that, in contrast to what could be suggested by in vitro studies, endogenous chronic hyperinsulinemia is not associated with an increase in the apoAI PR and is thus very unlikely to explain the overproduction of apoAI that is frequently observed in patients with metabolic syndrome. The kinetic data of HDL apoAI we report here for subjects with insulin resistance but not diabetes mellitus are consistent with previous reports by our and other research groups. Indeed, the FCR in patients with insulin resistance was 1.5× higher than that in lean control subjects with normal insulin sensitivity, which is characteristic of metabolic syndrome. 5, 7, 16 However, we observed a less important but significant increase in PR, similar to that reported by some previous studies. 5, 7 An increase in apoAI PR has also been reported in insulin-resistant subjects with diabetes mellitus, associated with a more important increase in FCR than in patients with metabolic syndrome without hyperglycemia. 4, 6, 8 In vitro studies on human hepatocarcinoma cells demonstrated the positive regulation of apoAI by insulin at the transcriptional level, which led us to hypothesize that hyperinsulinemia could explain the overproduction of apoAI in subjects with metabolic syndrome. If this hypothesis were true, we would have observed an overproduction of apoAI in patients with insulinoma, and we did not. The strength of our study is that the serum insulin level in our insulinresistant subjects was comparable with that in patients with insulinoma, and that in both groups of patients, hyperinsulinemia resulted from endogenous secretion with delivery in the portal vein. The reasons for the discrepancies between the results obtained on HepG2 cells and those of our in vivo kinetic study in patients with hyperinsulinemia are not clear. In vitro studies showed the induction of apoAI transcription with concentrations of insulin, such as 10 mU·L −1 , and greater transcription with insulin at 100 mU·L −1 . 15 ApoAI is mainly secreted by the liver, meaning that apoAI production strongly depends on insulinemia in the portal vein. As it is difficult to reach the portal vein, we were not able to measure portal insulinemia. However, we know that it is higher than peripheral insulinemia because of liver extraction. 17 Thus, given the results obtained in vitro, insulinemia in the portal vein of our patients with insulinoma was very probable in the range of concentrations that should have induced apoAI overproduction. Insulin has been shown to promote apoAI expression in studies using the rat genome. To our knowledge, no similar experiment has been performed with human genes. Species differences could explain the discrepancies between in vitro results obtained with the rat genome and our in vivo study performed in humans. Thus, our data strongly suggest that in humans, hyperinsulinemia is not likely to induce apoAI overproduction.
The mechanism responsible for the overproduction of apoAI in insulin-resistant states is not precisely known. An increase in HDL apoAI production concomitantly with an increased apoAI FCR has been reported in various pathological conditions, including metabolic syndrome and familial hypercholesterolemia or familial defective apoB 100 . [4] [5] [6] [7] [8] 18, 19 The increase in apoAI production is usually smaller than that in the FCR and has been reported as a balancing feedback mechanism to try and maintain the concentration of apoAI. 20 Our data are concordant with this hypothesis. Indeed, among the different parameters likely to influence the apoAI PR, the apoAI FCR showed the strongest correlation with the apoAI PR, in both the total population and each group separately. Moreover, in multivariate analysis, the apoAI FCR was the only parameter that correlated significantly with the apoAI PR and explained 80% of the variance. Chan et al 20 also reported a very strong correlation between these 2 parameters in both a subgroup of obese subjects and a subgroup of nonobese subjects. The molecular mechanisms underlying the correlation between the apoAI FCR and PR remain to be determined. In univariate analysis, the apoAI PR also correlated with HDL triglycerides and insulin resistance, but these correlations were no longer significant in multivariate analysis. This observation can be explained by the fact that HDL triglycerides (and triglyceridemia) and insulin resistance are major determinants of the HDL apoAI FCR, as clearly demonstrated by previous works. 4, 5, [20] [21] [22] [23] Indeed, hypertriglyceridemia stimulates the transfer of cholesteryl esters from HDL toward apoB-containing lipoproteins in exchange for triglycerides that are secondly hydrolyzed by hepatic lipase. This remodeling of HDL promotes the release of apoAI and the catabolism of both the released apoAI and the HDL remnants. 22, 24 Alternatively, one might speculate that the increase in apoAI PR is the primary abnormality in metabolic syndrome and is responsible for the increase in apoAI FCR. However, to our knowledge, no data in the literature sustain such an hypothesis. Indeed, beside metabolic syndrome, in some conditions HDL apoAI PR is increased and HDL particules are of smaller size, with no change in apoAI FCR. Such data have been observed, for example, in women on estrogen plus progestin as oral contraceptive. 24 An issue of our work is how hypoglycemia or the increased food intake might interfere with apoAI PR and our conclusion. On cultured cells glucose represses apoAI production. 25 Thus, hypoglycemia is unlikely to mask an increase in apoAI production induced by insulin. Moreover, insulin plus glucose increases apoAI production, as does insulin alone, which suggests that food intake associated with hyperinsulinemia did not mask an increase in apoAI production.
Our control subjects were younger than our patients with insulin resistance. However, age correlated negatively with the PR in the control group with a borderline significance (P=0.07) and no correlation was found in the group of patients with insulin resistance. Thus, the difference in age cannot explain the higher apoAI PR in patients with insulin resistance than in controls. However, the apoAI PR was also higher in patients with insulin resistance than in patients with insulinoma, although the age in these 2 groups was similar. We, therefore, think that endogenous hyperinsulinemia is not responsible for the increased apoAI PR, and that our results are not affected by differences in age.
In conclusion, in patients with insulinoma, showing chronic hyperinsulinemia without insulin resistance, there is no overproduction of HDL apoAI. These results indicate that hyperinsulinemia per se is not responsible for the increased PR of HDL apoAI observed in patients with metabolic syndrome.
